- $611.75m
- $497.16m
- $167.18m
- 81
- 27
- 69
- 61
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.66 | ||
| Price to Tang. Book | 3.66 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.66 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -17.34% | ||
| Return on Equity | -18.38% | ||
| Operating Margin | -21.08% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 73.39 | 90.15 | 106.41 | 138.89 | 167.18 | 194.25 | 226.09 | 19.96% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
Directors
- Jeffrey Dunn CHM (66)
- Laura Francis CEO (54)
- Anshul Maheshwari CFO (41)
- Anthony Recupero CEX (62)
- Michael Pisetsky SVP (43)
- Timothy Davis LED (51)
- John Freund IND (67)
- Jeryl Hilleman IND (63)
- Gregory Hinckley IND (73)
- Helen Loh IND (58)
- Mika Nishimura IND (58)
- Keith Valentine IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 18th, 2008
- Public Since
- October 17th, 2018
- No. of Shareholders
- 116
- No. of Employees
- 349
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 42,453,116
- Address
- 471 El Camino Real, Suite 101, SANTA CLARA, 95050
- Web
- https://si-bone.com/
- Phone
- +1 4082070700
- Auditors
- PricewaterhouseCoopers LLP
Latest News for SIBN
Upcoming Events for SIBN
Q1 2025 SI-BONE Inc Earnings Release
Q1 2025 SI-BONE Inc Earnings Call
SI-BONE Inc Annual Shareholders Meeting
SI-BONE Inc Annual Shareholders Meeting
Q2 2025 SI-BONE Inc Earnings Release
Similar to SIBN
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Beta Bionics
NASDAQ Global Market
FAQ
As of Today at 23:13 UTC, shares in SI-Bone are trading at $14.41. This share price information is delayed by 15 minutes.
Shares in SI-Bone last closed at $14.41 and the price had moved by +0.98% over the past 365 days. In terms of relative price strength the SI-Bone share price has underperformed the S&P500 Index by -6.79% over the past year.
The overall consensus recommendation for SI-Bone is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreSI-Bone does not currently pay a dividend.
SI-Bone does not currently pay a dividend.
SI-Bone does not currently pay a dividend.
To buy shares in SI-Bone you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $14.41, shares in SI-Bone had a market capitalisation of $611.75m.
Here are the trading details for SI-Bone:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: SIBN
Based on an overall assessment of its quality, value and momentum SI-Bone is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in SI-Bone is $24.38. That is 69.19% above the last closing price of $14.41.
Analysts covering SI-Bone currently have a consensus Earnings Per Share (EPS) forecast of -$0.68 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SI-Bone. Over the past six months, its share price has outperformed the S&P500 Index by +19.87%.
As of the last closing price of $14.41, shares in SI-Bone were trading -2.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The SI-Bone PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $14.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
SI-Bone's management team is headed by:
- Jeffrey Dunn - CHM
- Laura Francis - CEO
- Anshul Maheshwari - CFO
- Anthony Recupero - CEX
- Michael Pisetsky - SVP
- Timothy Davis - LED
- John Freund - IND
- Jeryl Hilleman - IND
- Gregory Hinckley - IND
- Helen Loh - IND
- Mika Nishimura - IND
- Keith Valentine - IND